Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
Cassava Sciences (NASDAQ:SAVA) is extending ongoing open-label extension trials of its lead drug candidate, simufilam, in Alzheimer’s disease by up to an additional 36 months. “Cassava Sciences will ...
Hosted on MSN
Alterity reports positive results from open-label phase II trial of neurological disease drug
Alterity reports positive topline data from open-label phase II trial of ATH434 in multiple system atrophy ATH434 demonstrated clinical benefit on Unified MSA Rating Scale and global measures of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results